Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.
Identifieur interne : 002465 ( PubMed/Curation ); précédent : 002464; suivant : 002466Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.
Auteurs : Karen M. Powers [États-Unis] ; Denise M. Kay ; Stewart A. Factor ; Cyrus P. Zabetian ; Donald S. Higgins ; Ali Samii ; John G. Nutt ; Alida Griffith ; Berta Leis ; John W. Roberts ; Erica D. Martinez ; Jennifer S. Montimurro ; Harvey Checkoway ; Haydeh PayamiSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2008.
English descriptors
- KwdEn :
- Aged, Anti-Inflammatory Agents, Non-Steroidal (administration & dosage), Anti-Inflammatory Agents, Non-Steroidal (pharmacology), Caffeine (administration & dosage), Caffeine (pharmacology), Central Nervous System Stimulants (administration & dosage), Central Nervous System Stimulants (pharmacology), Coffee, Cognition (drug effects), Drinking Behavior, Female, Humans, Male, Nicotine (administration & dosage), Nicotine (pharmacology), Parkinson Disease (epidemiology), Parkinson Disease (physiopathology), Parkinson Disease (prevention & control), Prevalence, Questionnaires, Smoking (epidemiology).
- MESH :
- chemical , administration & dosage : Anti-Inflammatory Agents, Non-Steroidal, Caffeine, Central Nervous System Stimulants, Nicotine.
- chemical , pharmacology : Anti-Inflammatory Agents, Non-Steroidal, Caffeine, Central Nervous System Stimulants, Nicotine.
- drug effects : Cognition.
- epidemiology : Parkinson Disease, Smoking.
- physiopathology : Parkinson Disease.
- prevention & control : Parkinson Disease.
- Aged, Coffee, Drinking Behavior, Female, Humans, Male, Prevalence, Questionnaires.
Abstract
Inverse associations of Parkinson's disease (PD) with cigarette smoking, coffee drinking, and nonsteroidal anti-inflammatory drug (NSAID) use have been reported individually, but their joint effects have not been examined. To quantify associations with PD for the individual, two-way and three-way combinations of these factors, a case-control association study with 1,186 PD patients and 928 controls was conducted. The study setting was the NeuroGenetics Research Consortium. Subjects completed a structured questionnaire regarding smoking, coffee, and NSAID consumption. Odds ratios were calculated using unconditional logistic regression. Smoking, coffee, and over the counter NSAID use as individual factors exhibited significantly reduced risks of 20% to 30%. The two-way and three-way combinations were associated with risk reduction of 37% to 49%, and 62%, respectively. Smoking and coffee exhibited significant inverse risk trends with increasing cumulative exposures, suggesting dose-response relations. With respect to the combination of all three exposures, persons who were at the highest exposure strata for smoking and coffee and used NSAIDs had an estimated 87% reduction in risk (OR = 0.13, 95% CI = 0.06-0.29). Whether this finding reflects true biologic protection needs to be investigated.
DOI: 10.1002/mds.21782
PubMed: 17987647
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002465
Links to Exploration step
pubmed:17987647Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.</title><author><name sortKey="Powers, Karen M" sort="Powers, Karen M" uniqKey="Powers K" first="Karen M" last="Powers">Karen M. Powers</name><affiliation wicri:level="1"><nlm:affiliation>Department of Environmental and Occupational Health Sciences, School of Public Health and Community Medicine, University of Washington, Seattle, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, School of Public Health and Community Medicine, University of Washington, Seattle, Washington</wicri:regionArea></affiliation></author><author><name sortKey="Kay, Denise M" sort="Kay, Denise M" uniqKey="Kay D" first="Denise M" last="Kay">Denise M. Kay</name></author><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A" last="Factor">Stewart A. Factor</name></author><author><name sortKey="Zabetian, Cyrus P" sort="Zabetian, Cyrus P" uniqKey="Zabetian C" first="Cyrus P" last="Zabetian">Cyrus P. Zabetian</name></author><author><name sortKey="Higgins, Donald S" sort="Higgins, Donald S" uniqKey="Higgins D" first="Donald S" last="Higgins">Donald S. Higgins</name></author><author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name></author><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G" last="Nutt">John G. Nutt</name></author><author><name sortKey="Griffith, Alida" sort="Griffith, Alida" uniqKey="Griffith A" first="Alida" last="Griffith">Alida Griffith</name></author><author><name sortKey="Leis, Berta" sort="Leis, Berta" uniqKey="Leis B" first="Berta" last="Leis">Berta Leis</name></author><author><name sortKey="Roberts, John W" sort="Roberts, John W" uniqKey="Roberts J" first="John W" last="Roberts">John W. Roberts</name></author><author><name sortKey="Martinez, Erica D" sort="Martinez, Erica D" uniqKey="Martinez E" first="Erica D" last="Martinez">Erica D. Martinez</name></author><author><name sortKey="Montimurro, Jennifer S" sort="Montimurro, Jennifer S" uniqKey="Montimurro J" first="Jennifer S" last="Montimurro">Jennifer S. Montimurro</name></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name></author><author><name sortKey="Payami, Haydeh" sort="Payami, Haydeh" uniqKey="Payami H" first="Haydeh" last="Payami">Haydeh Payami</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="doi">10.1002/mds.21782</idno><idno type="RBID">pubmed:17987647</idno><idno type="pmid">17987647</idno><idno type="wicri:Area/PubMed/Corpus">002465</idno><idno type="wicri:Area/PubMed/Curation">002465</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.</title><author><name sortKey="Powers, Karen M" sort="Powers, Karen M" uniqKey="Powers K" first="Karen M" last="Powers">Karen M. Powers</name><affiliation wicri:level="1"><nlm:affiliation>Department of Environmental and Occupational Health Sciences, School of Public Health and Community Medicine, University of Washington, Seattle, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Environmental and Occupational Health Sciences, School of Public Health and Community Medicine, University of Washington, Seattle, Washington</wicri:regionArea></affiliation></author><author><name sortKey="Kay, Denise M" sort="Kay, Denise M" uniqKey="Kay D" first="Denise M" last="Kay">Denise M. Kay</name></author><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A" last="Factor">Stewart A. Factor</name></author><author><name sortKey="Zabetian, Cyrus P" sort="Zabetian, Cyrus P" uniqKey="Zabetian C" first="Cyrus P" last="Zabetian">Cyrus P. Zabetian</name></author><author><name sortKey="Higgins, Donald S" sort="Higgins, Donald S" uniqKey="Higgins D" first="Donald S" last="Higgins">Donald S. Higgins</name></author><author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name></author><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G" last="Nutt">John G. Nutt</name></author><author><name sortKey="Griffith, Alida" sort="Griffith, Alida" uniqKey="Griffith A" first="Alida" last="Griffith">Alida Griffith</name></author><author><name sortKey="Leis, Berta" sort="Leis, Berta" uniqKey="Leis B" first="Berta" last="Leis">Berta Leis</name></author><author><name sortKey="Roberts, John W" sort="Roberts, John W" uniqKey="Roberts J" first="John W" last="Roberts">John W. Roberts</name></author><author><name sortKey="Martinez, Erica D" sort="Martinez, Erica D" uniqKey="Martinez E" first="Erica D" last="Martinez">Erica D. Martinez</name></author><author><name sortKey="Montimurro, Jennifer S" sort="Montimurro, Jennifer S" uniqKey="Montimurro J" first="Jennifer S" last="Montimurro">Jennifer S. Montimurro</name></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name></author><author><name sortKey="Payami, Haydeh" sort="Payami, Haydeh" uniqKey="Payami H" first="Haydeh" last="Payami">Haydeh Payami</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)</term><term>Anti-Inflammatory Agents, Non-Steroidal (pharmacology)</term><term>Caffeine (administration & dosage)</term><term>Caffeine (pharmacology)</term><term>Central Nervous System Stimulants (administration & dosage)</term><term>Central Nervous System Stimulants (pharmacology)</term><term>Coffee</term><term>Cognition (drug effects)</term><term>Drinking Behavior</term><term>Female</term><term>Humans</term><term>Male</term><term>Nicotine (administration & dosage)</term><term>Nicotine (pharmacology)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (prevention & control)</term><term>Prevalence</term><term>Questionnaires</term><term>Smoking (epidemiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Caffeine</term><term>Central Nervous System Stimulants</term><term>Nicotine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Caffeine</term><term>Central Nervous System Stimulants</term><term>Nicotine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cognition</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term><term>Smoking</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Coffee</term><term>Drinking Behavior</term><term>Female</term><term>Humans</term><term>Male</term><term>Prevalence</term><term>Questionnaires</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Inverse associations of Parkinson's disease (PD) with cigarette smoking, coffee drinking, and nonsteroidal anti-inflammatory drug (NSAID) use have been reported individually, but their joint effects have not been examined. To quantify associations with PD for the individual, two-way and three-way combinations of these factors, a case-control association study with 1,186 PD patients and 928 controls was conducted. The study setting was the NeuroGenetics Research Consortium. Subjects completed a structured questionnaire regarding smoking, coffee, and NSAID consumption. Odds ratios were calculated using unconditional logistic regression. Smoking, coffee, and over the counter NSAID use as individual factors exhibited significantly reduced risks of 20% to 30%. The two-way and three-way combinations were associated with risk reduction of 37% to 49%, and 62%, respectively. Smoking and coffee exhibited significant inverse risk trends with increasing cumulative exposures, suggesting dose-response relations. With respect to the combination of all three exposures, persons who were at the highest exposure strata for smoking and coffee and used NSAIDs had an estimated 87% reduction in risk (OR = 0.13, 95% CI = 0.06-0.29). Whether this finding reflects true biologic protection needs to be investigated.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17987647</PMID><DateCreated><Year>2008</Year><Month>01</Month><Day>31</Day></DateCreated><DateCompleted><Year>2008</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.</ArticleTitle><Pagination><MedlinePgn>88-95</MedlinePgn></Pagination><Abstract><AbstractText>Inverse associations of Parkinson's disease (PD) with cigarette smoking, coffee drinking, and nonsteroidal anti-inflammatory drug (NSAID) use have been reported individually, but their joint effects have not been examined. To quantify associations with PD for the individual, two-way and three-way combinations of these factors, a case-control association study with 1,186 PD patients and 928 controls was conducted. The study setting was the NeuroGenetics Research Consortium. Subjects completed a structured questionnaire regarding smoking, coffee, and NSAID consumption. Odds ratios were calculated using unconditional logistic regression. Smoking, coffee, and over the counter NSAID use as individual factors exhibited significantly reduced risks of 20% to 30%. The two-way and three-way combinations were associated with risk reduction of 37% to 49%, and 62%, respectively. Smoking and coffee exhibited significant inverse risk trends with increasing cumulative exposures, suggesting dose-response relations. With respect to the combination of all three exposures, persons who were at the highest exposure strata for smoking and coffee and used NSAIDs had an estimated 87% reduction in risk (OR = 0.13, 95% CI = 0.06-0.29). Whether this finding reflects true biologic protection needs to be investigated.</AbstractText><CopyrightInformation>2007 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Powers</LastName><ForeName>Karen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Environmental and Occupational Health Sciences, School of Public Health and Community Medicine, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kay</LastName><ForeName>Denise M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Factor</LastName><ForeName>Stewart A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Zabetian</LastName><ForeName>Cyrus P</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Higgins</LastName><ForeName>Donald S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Samii</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Nutt</LastName><ForeName>John G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Griffith</LastName><ForeName>Alida</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Leis</LastName><ForeName>Berta</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>John W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Erica D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Montimurro</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Checkoway</LastName><ForeName>Harvey</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Payami</LastName><ForeName>Haydeh</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 08017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08-NS044138</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS036960</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003069">Coffee</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G6A5W338E</RegistryNumber><NameOfSubstance UI="D002110">Caffeine</NameOfSubstance></Chemical><Chemical><RegistryNumber>54-11-5</RegistryNumber><NameOfSubstance UI="D009538">Nicotine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002110">Caffeine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000697">Central Nervous System Stimulants</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D003069">Coffee</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003071">Cognition</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D004327">Drinking Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009538">Nicotine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012907">Smoking</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21782</ArticleId><ArticleId IdType="pubmed">17987647</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002465 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002465 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:17987647
|texte= Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:17987647" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |